Download PDF
Hamostaseologie 2019; 39(03): 266-271
DOI: 10.1055/s-0039-1684032
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Immunomodulatory Second-Line Therapies for Immune Thrombocytopenia

Michele P. Lambert
1   Division of Hematology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
2   Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
› Author Affiliations
Further Information

Publication History

06 September 2018

14 February 2019

Publication Date:
05 June 2019 (online)

Also available at
   Permissions and Reprints

Abstract

Management of immune thrombocytopenia (ITP) is complex requiring communication between patients and caregivers to establish a mutual understanding of the impact of the patient's disease on quality of life, the current symptoms and risk of morbidity/mortality and the goals of therapy. The currently available second-line therapies for ITP provide potential for management of thrombocytopenia and bleeding symptoms with medical therapy or surgical intervention potentially offering long-term remission. All therapies are associated with potential side effects and necessary monitoring or modifications/risks and careful discussion of these is necessary to determine the optimal therapy for each patient. This review covers second-line therapies for ITP and discusses the currently available information on immunomodulatory second-line treatments for ITP.

Keywords

autoimmune disease - platelet - ITP - treatment
 

  • References

  • 1 Moulis G, Palmaro A, Montastruc JL, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood 2014; 124 (22) 3308-3315
    PubMedGoogle Scholar
  • 2 Fogarty PF, Segal JB. The epidemiology of immune thrombocytopenic purpura. Curr Opin Hematol 2007; 14 (05) 515-519
    CrossrefPubMedGoogle Scholar
  • 3 Schifferli A, Holbro A, Chitlur M. , et al; Intercontinental Cooperative ITP Study Group (ICIS). A comparative prospective observational study of children and adults with immune thrombocytopenia: 2-year follow-up. Am J Hematol 2018; 93 (06) 751-759
    CrossrefPubMedGoogle Scholar
  • 4 Neunert C, Lim W, Crowther M, Cohen A, Solberg Jr L, Crowther MA. ; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117 (16) 4190-4207
    CrossrefPubMedGoogle Scholar
  • 5 Rodeghiero F, Stasi R, Gernsheimer T. , et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113 (11) 2386-2393
    CrossrefPubMedGoogle Scholar
  • 6 Chaturvedi S, Arnold DM, McCrae KR. Splenectomy for immune thrombocytopenia: down but not out. Blood 2018; 131 (11) 1172-1182
    CrossrefPubMedGoogle Scholar
  • 7 Tamary H, Roganovic J, Chitlur M, Nugent DJ. Consensus Paper-ICIS Expert Meeting Basel 2009 treatment milestones in immune thrombocytopenia. Ann Hematol 2010; 89 (Suppl. 01) 5-10
    CrossrefPubMedGoogle Scholar
  • 8 Kaznelson P. Verschwinden der hamorrhagischen Diathese bei einem Fane von “essentieller Thrombopenie” (Frank) nach Milzextirpation. Klin Wochenschr 1916; 29: 1451-1454
    PubMedGoogle Scholar
  • 9 Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104 (09) 2623-2634
    PubMedGoogle Scholar
  • 10 Gwilliam NR, Lazar DA, Brandt ML. , et al. An analysis of outcomes and treatment costs for children undergoing splenectomy for chronic immune thrombocytopenia purpura. J Pediatr Surg 2012; 47 (08) 1537-1541
    CrossrefPubMedGoogle Scholar
  • 11 Palandri F, Polverelli N, Sollazzo D. , et al. Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years. Am J Hematol 2016; 91 (04) E267-E272
    CrossrefPubMedGoogle Scholar
  • 12 Kumar S, Diehn FE, Gertz MA, Tefferi A. Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses. Ann Hematol 2002; 81 (06) 312-319
    CrossrefPubMedGoogle Scholar
  • 13 Ahmed R, Devasia AJ, Viswabandya A. , et al. Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children : Splenectomy in ITP. Ann Hematol 2016; 95 (09) 1429-1434
    CrossrefPubMedGoogle Scholar
  • 14 Thai LH, Mahévas M, Roudot-Thoraval F. , et al. Long-term complications of splenectomy in adult immune thrombocytopenia. Medicine (Baltimore) 2016; 95 (48) e5098
    PubMedGoogle Scholar
  • 15 Guan Y, Wang S, Xue F. , et al. Long-term results of splenectomy in adult chronic immune thrombocytopenia. Eur J Haematol 2017; 98 (03) 235-241
    CrossrefPubMedGoogle Scholar
  • 16 Shatz DV. Vaccination considerations in the asplenic patient. Expert Rev Vaccines 2005; 4 (01) 27-34
    CrossrefPubMedGoogle Scholar
  • 17 Rodeghiero F. A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP. Br J Haematol 2018; 181 (02) 183-195
    CrossrefPubMedGoogle Scholar
  • 18 Wang KK, Charles C, Heddle NM, Arnold E, Molnar L, Arnold DM. Understanding why patients with immune thrombocytopenia are deeply divided on splenectomy. Health Expect 2014; 17 (06) 809-817
    CrossrefPubMedGoogle Scholar
  • 19 Cuker A, Cines DB, Neunert CE. Controversies in the treatment of immune thrombocytopenia. Curr Opin Hematol 2016; 23 (05) 479-485
    CrossrefPubMedGoogle Scholar
  • 20 Chugh S, Darvish-Kazem S, Lim W. , et al. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol 2015; 2 (02) e75-e81
    PubMedGoogle Scholar
  • 21 Ghanima W, Khelif A, Waage A. , et al; RITP study group. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015; 385 (9978): 1653-1661
    CrossrefPubMedGoogle Scholar
  • 22 Moulis G, Lapeyre-Mestre M, Mahévas M, Montastruc JL, Sailler L. Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France. Am J Hematol 2015; 90 (04) 301-305
    CrossrefPubMedGoogle Scholar
  • 23 Kapoor R, Kumar R, Mahapatra M, Pati HP, Pramanik SK. Low dose rituximab in chronic ITP: still an option in resource limited settings. Indian J Hematol Blood Transfus 2017; 33 (04) 568-573
    CrossrefPubMedGoogle Scholar
  • 24 Tran H, Brighton T, Grigg A. , et al. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study). Br J Haematol 2014; 167 (02) 243-251
    CrossrefPubMedGoogle Scholar
  • 25 Choi PY, Roncolato F, Badoux X, Ramanathan S, Ho SJ, Chong BH. A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). Blood 2015; 126 (04) 500-503
    PubMedGoogle Scholar
  • 26 Li Y, Wang YY, Fei HR, Wang L, Yuan CL. Efficacy of low-dose rituximab in combination with recombinant human thrombopoietin in treating ITP. Eur Rev Med Pharmacol Sci 2015; 19 (09) 1583-1588
    PubMedGoogle Scholar
  • 27 Weber E, Reynaud Q, Fort R. , et al. Immunomodulatory treatments for persistent and chronic immune thrombocytopenic purpura: a PRISMA-compliant systematic review and meta-analysis of 28 studies. Medicine (Baltimore) 2017; 96 (37) e7534
    PubMedGoogle Scholar
  • 28 Lee JY, Lee JO, Jung JY, Bang SM. Dapsone therapy for refractory immune thrombocytopenia patients: a case series. Blood Res 2017; 52 (02) 95-99
    CrossrefPubMedGoogle Scholar
  • 29 Estève C, Samson M, Guilhem A. , et al. Efficacy and safety of dapsone as second line therapy for adult immune thrombocytopenia: a retrospective study of 42 patients. PLoS One 2017; 12 (10) e0187296
    CrossrefPubMedGoogle Scholar
  • 30 Damodar S, Viswabandya A, George B, Mathews V, Chandy M, Srivastava A. Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults--a report on 90 patients. Eur J Haematol 2005; 75 (04) 328-331
    CrossrefPubMedGoogle Scholar
  • 31 Sauvetre G, MahÉvas M, Limal N. , et al. Cutaneous rash and dapsone-induced hypersensitivity syndrome a common manifestation in adult immune thrombocytopenia. Presentation and outcome in 16 cases. Am J Hematol 2015; 90 (10) E201-E202
    CrossrefPubMedGoogle Scholar
  • 32 Zhang FR, Liu H, Irwanto A. , et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med 2013; 369 (17) 1620-1628
    CrossrefPubMedGoogle Scholar
  • 33 Schwartz R, Dameshek W. The treatment of autoimmune hemolytic anemia with 6-mercaptopurine and thioguanine. Blood 1962; 19: 483-500
    CrossrefPubMedGoogle Scholar
  • 34 Sobota A, Neufeld EJ, Lapsia S, Bennett CM. Response to mercaptopurine for refractory autoimmune cytopenias in children. Pediatr Blood Cancer 2009; 52 (01) 80-84
    CrossrefPubMedGoogle Scholar
  • 35 Quiquandon I, Fenaux P, Caulier MT, Pagniez D, Huart JJ, Bauters F. Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases. Br J Haematol 1990; 74 (02) 223-228
    CrossrefPubMedGoogle Scholar
  • 36 Verlin M, Laros Jr RK, Penner JA. Treatment of refractory thrombocytopenic purpura with cyclophosphamine. Am J Hematol 1976; 1 (01) 97-104
    CrossrefPubMedGoogle Scholar
  • 37 Berchtold P, McMillan R. Therapy of chronic idiopathic thrombocytopenic purpura in adults. Blood 1989; 74 (07) 2309-2317
    CrossrefPubMedGoogle Scholar
  • 38 Provan D, Moss AJ, Newland AC, Bussel JB. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol 2006; 81 (01) 19-25
    CrossrefPubMedGoogle Scholar
  • 39 Emilia G, Morselli M, Luppi M. , et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood 2002; 99 (04) 1482-1485
    CrossrefPubMedGoogle Scholar
  • 40 Kappers-Klunne MC, van't Veer MB. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol 2001; 114 (01) 121-125
    CrossrefPubMedGoogle Scholar
  • 41 Moskowitz IP, Gaynon PS, Shahidi NT, Cripe TP. Low-dose cyclosporin A therapy in children with refractory immune thrombocytopenic purpura. J Pediatr Hematol Oncol 1999; 21 (01) 77-79
    PubMedGoogle Scholar
  • 42 Howard J, Hoffbrand AV, Prentice HG, Mehta A. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br J Haematol 2002; 117 (03) 712-715
    CrossrefPubMedGoogle Scholar
  • 43 Hou M, Peng J, Shi Y. , et al. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol 2003; 70 (06) 353-357
    CrossrefPubMedGoogle Scholar
  • 44 Zhang WG, Ji L, Cao XM. , et al. Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura. Acta Pharmacol Sin 2005; 26 (05) 598-602
    CrossrefPubMedGoogle Scholar
  • 45 Taylor A, Neave L, Solanki S. , et al. Mycophenolate mofetil therapy for severe immune thrombocytopenia. Br J Haematol 2015; 171 (04) 625-630
    CrossrefPubMedGoogle Scholar
  • 46 Miano M, Ramenghi U, Russo G. , et al. Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian association of paediatric haematology/oncology. Br J Haematol 2016; 175 (03) 490-495
    CrossrefPubMedGoogle Scholar
  • 47 Bussel J, Arnold DM, Grossbard E. , et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol 2018; 93 (07) 921-930
    CrossrefPubMedGoogle Scholar
  • 48 Newland A, Lee EJ, McDonald V, Bussel JB. Fostamatinib for persistent/chronic adult immune thrombocytopenia. Immunotherapy 2018; 10 (01) 9-25
    CrossrefPubMedGoogle Scholar
  • 49 Erratum for the Research Article. Erratum for the research article: “The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study” by P. Kiessling, R. Lledo-Garcia, S. Watanabe, G. Langdon, D. Tran, M. Bari, L. Christodoulou, E. Jones, G. Price, B. Smith, F. Brennan, I. White, S. Jolles. Sci Transl Med 2017; 9 (419) eaar6448
    CrossrefPubMedGoogle Scholar
  • 50 Kiessling P, Lledo-Garcia R, Watanabe S. , et al. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study. Sci Transl Med 2017; 9 (414) eaan1208
    CrossrefPubMedGoogle Scholar